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Summary
AIMS OF THE STUDY: The Cancer Registry Zurich, Zug,
Schaffhausen and Schwyz is one of the oldest cancer reg-
istries in Switzerland, first registering tumours in 1980 for
the canton of Zurich. The aim of this study was to analyse
trends in incidence and mortality for the most common
types of cancer in the canton of Zurich from 1981 to 2017.
METHODS: In this analysis of population-based cancer
registry data, we included malignant tumours of the breast
(ICD10 C50), prostate (C61), colon/rectum (C18–C21),
lung (C33–C34), and melanoma (C43), diagnosed be-
tween 1981 and 2017. Age-standardised incidence and
mortality rates per 100,000 person-years were computed
using the 1976 European Standard Population. Incidence
and mortality time trends were assessed using joinpoint
regression analysis.
RESULTS: In men, incidence for prostate cancer and
melanoma increased over the study period, while it de-
creased for colon/rectum and lung cancer. A joinpoint for
prostate cancer indicated the start of a decreasing trend
in 2002. In women, incidence increased for breast cancer,
lung cancer and melanoma; no trend was observed for
colon/rectum cancer. Cancer mortality decreased for
prostate, colon/rectum and lung cancer in men, with no
clear trend for melanoma. In women, mortality decreased
for breast cancer, colon/rectum cancer and melanoma, but
increased for lung cancer.
CONCLUSIONS: The overall increasing incidence trends
for prostate and breast cancer, as well as for melanoma,
are in line with data from other Western countries. While
lung cancer incidence is decreasing in men, it is still on the
rise in women. Despite increasing incidence rates, mortal-
ity rates are decreasing for all localisations except for lung
cancer in women. The opposite direction of incidence and
mortality curves is probably mostly due to better and more
effective treatment options, as well as earlier detection.
Keywords: breast cancer, prostate cancer, melanoma,
lung cancer, colon/rectum cancer, time trends, Switzer-
land, incidence, mortality
Introduction
As in many European countries, the most common types
of cancer in Switzerland are breast (women) and prostate
(men), lung and colon/rectum cancer [1]. In addition,
melanoma ranks among the five most common types of
cancer. These national trends are also observed in the can-
ton of Zurich, which is the largest Swiss canton with a pop-
ulation of about 1.5 million in 2017 [2].
In 2017, more than 1,000 new cases of prostate and breast
cancer were diagnosed in the canton of Zurich. Further-
more, we registered around 720 new colorectal cancer cas-
es, 790 new lung cancer cases, and 620 new melanomas.
Due to an increase in the population of the canton of
Zurich of more than 30% between 1980 and 2017, the ab-
solute numbers of new cancer cases increased. Therefore,
age-standardised incidence and mortality rates per 100,000
are the most appropriate measures to study these changes,
since they take into account the size of the population as
well as its age structure. Nevertheless, changes in the ab-
solute numbers are of interest, especially regarding health
system costs.
Cancer registration in the canton of Zurich dates back to
1980. This provides the opportunity to look at time trends
for more than 35 years regarding incidence and mortal-
ity of common types of cancer. Time trends are of in-
terest for several reasons: they reflect changes in screen-
ing behaviour, effects of prevention efforts and health care
planning, adaptions in treatment guidelines and treatment
techniques, changes in the population distribution, etc.
Furthermore, time trends may have an impact on future
health care and prevention planning, and may affect the
elaboration of guidelines regarding treatment and screen-
ing.
The availability of variables such as sex, age, and stage
at tumour diagnosis further allows for stratifying analyses
and investigating potentially diverging trends in sub-
groups. For example, screening efforts may lead to a spe-
cific increase in localised tumours [3]. Moreover, changes
in stage distribution at diagnosis, as well as improvement
in treatments, may affect mortality rates [3].
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The aim of the present study was to present time trends in
incidence and mortality rates for the most common types
of cancer from 1981 to 2017 in the canton of Zurich,
Switzerland. For more in-depth insights, trends were strat-
ified by sex and age group and, for incidence rates, addi-
tionally by stage.
Materials and methods
Data
Cancer registration in Switzerland is mandatory from 2020
onwards, based on a national law. However, mainly based
on cantonal legislation, several cantons have started to
register cancer data much earlier, with the oldest registry
dating back to the 1970s. The population-based cancer
registry of the cantons of Zurich, Zug, Schaffhausen and
Schwyz started registering data in 1980 for Zurich, in 2011
for Zug, while Schaffhausen and Schwyz joined the reg-
istry in 2020. The patient’s main place of residence at the
time of diagnosis is the criterion for inclusion in the re-
spective cantonal cancer registry. For the present analysis,
we only included data from the canton of Zurich in order
to investigate trends over more than 30 years. Compared to
the whole country, the canton of Zurich is an urban canton
with slightly more individuals between 20 and 39 years,
and fewer above 60 years. Furthermore, the proportion of
non-Swiss individuals is slightly higher in Zurich than in
Switzerland.
We included malignant tumours of the breast (C50 accord-
ing to the International Statistical Classification of Dis-
eases and Related Health Problems 10th Revision
(ICD10)), prostate (C61), colon/rectum (C18–C21), and
lung (C33–C34), as well as melanoma (C43), diagnosed in
the canton of Zurich between 1981 and 2017. The reason
for inclusion from 1981 instead of 1980 is that population
files are only available from 1981 onwards. For stage-strat-
ified analyses, we used only the period 2003–2017 because
the recording of cancer stage was not systematic prior to
2003.
The incidence dataset includes data on the date of diagno-
sis, the ICD10 code for tumour localisation, age at diag-
nosis, as well as clinical and pathological TNM (tumour –
node – metastasis) to define stage.
In general, the quality of the Zurich cancer registry data
is good [4]. The percentage of death certificate only cases
(DCO) was 2.6% for the period 1997–2014, and the per-
centage of morphologically verified cases (MV) was
93.3%. The percentage of DCO was highest for lung can-
cer (3.4%) and lowest for melanoma (0.2%). The percent-
age of MV was lowest for lung cancer (90.4%) and highest
for melanoma (99.6%).
The mortality data were provided by the Swiss Federal Sta-
tistical Office and are based on the national statistics for
cause of death. We used data from 1981 to 2017. The main
cause of death was coded according to the 8th revision of
the ICD (ICD8) up to 1994, and according to ICD10 from
1995 onwards. In our mortality analyses, we used the same
cancer codes as for incidence.
Statistical analyses
Age-standardised incidence and mortality rates per
100,000 person-years were computed using the 1976 Euro-
pean Standard Population [5] (which has often been used
in other studies and thus allows for comparison with other
studies) and mid-year population estimates.
For the age-stratified analyses, the following age groups
were used for prostate, lung, and colon/rectum cancer: <60
years, 60–69 years, 70–79 years, ≥80 years. For breast
cancer and melanoma, an additional (younger) age group
was included (<50 years, 50–59 years, 60-69 years, 70–79
years, ≥80 years), because these cancers frequently occur
at younger ages. For the stage-stratified analyses, we used
the stages I, II, III, IV and a ‘missing stage’. Based on
pathological and/or clinical TNM, stage was defined sepa-
rately for each localisation according to the TNM classifi-
cation of malignant tumours version 6 (for incidence year
up to 2009) and version 7 (from incidence year 2010 on-
wards) [6, 7]. Pathological TNM (pTNM) was used when
available; otherwise, clinical TNM (cTNM) was used.
Missing cM was assumed to be zero, while missing N
and T were set to ‘missing’ if both clinical and patholog-
ical N/T were missing. For breast cancer and melanoma,
missing pN/cN were set to zero if cT/pT=1. For example,
melanomas with a thickness of 1 mm or thinner (T1) are
typically localised and considered non-metastatic, hence
why patients with these lesions are often not offered sen-
tinel node operation and further examination [8].
Stata/SE Version 15 was used to prepare the data for fur-
ther processing in the JoinPoint Trend Analysis Software.
Incidence and mortality time trends were assessed using
joinpoint regression analysis (JoinPoint Trend Analysis
Software Version 4.6.0.0, April 2018; US National Cancer
Institute, Division of Cancer Control and Population Sci-
ences, Surveillance Research Program). This method is
used to determine the number of joinpoints that are ade-
quate for assessing significant changes in trends over time.
The analysis starts with 0 joinpoints (corresponding to a
straight regression line), and tests whether one or more
joinpoints are significant, using the permutation test. The
Grid Search Method and the Monte Carlo permutation
method, with 4499 replicates and a significance level of
0.05, were used [9]. We defined the maximum number of
joinpoints as five for general and age-stratified analyses
(1981–2017), and as two for stage-stratified analyses
(2003-2017), based on the recommendations in the Join-
point Manual. Furthermore, we defined the minimum num-
ber of observations from a joinpoint to either end of the
data as two, and the minimum number of observations be-
tween two joinpoints as two (including any joinpoint that
falls on an observation). The dependent variables were the
age-standardised incidence and mortality rates; the inde-
pendent variable was calendar year. Age group/stage were
defined as by-variables. The relevant results from these
analyses are the annual percentage changes (APC) for each
identified trend between two joinpoints, as well as the av-
erage annual percentage change (AAPC), a summary mea-
sure over the whole period of observations (1981–2017
for overall and age-stratified incidence and mortality;
2003-2017 for stage-stratified incidence). Log-transforma-
tion of the dependent variable (age-standardised incidence
and mortality) was used because of non-normality of the
data. The AAPC are presented with 95% confidence in-
tervals (95% CI). R Version 3.6.1 was used to create the
graphs.
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Results
Table 1 displays the number of cancer cases by localisa-
tion, sex, and age group for incidence and mortality.
Incidence trends in general
Figures 1A and 1B present the sex-stratified incidence
trends for cancers of the prostate, breast, colon/rectum, and
lung, as well as for melanoma, from 1981 to 2017 in the
canton of Zurich, Switzerland. The AAPC are displayed
in supplementary table S1 (appendix 1). In men, the inci-
dence trend linearly decreased for colon/rectum and lung
cancer with statistically significant AAPC of −0.2 (95% CI
−0.4 to −0.0) and −1.5 (95% CI −1.7 to −1.4), respective-
ly. For prostate cancer, a joinpoint was detected in 2002
marking a change in the incidence trend from increasing
to decreasing (APC 1981–2002: 2.9 (95% CI 2.6 to 3.3)
vs APC 2002–2011: –0.8 (95% CI –2.0 to 0.4)). A join-
point in 2011 indicated an even steeper decrease until 2014
(APC 2011–2014: –6.7 (95% CI –16.3 to 4.0), and a join-
point in 2014 indicated a change towards an increasing
trend (APC 2014–2017: 6.6 (95% CI 1.1 to 12.3)). In men,
no joinpoints were detected for the other localisations.
In women, the incidence trends were significantly increas-
ing for all localisations except for colon/rectum, with
AAPC of 3.0 (95% CI 2.7 to 3.4) for lung cancer and
2.3 (95% CI 1.9 to 2.7) for melanoma. For breast cancer,
Figure 1: Age-standardised incidence and mortality rates for can-
cers of the prostate, breast, colon/rectum, and lung, as well as for
melanoma from 1981 to 2017, by sex, in the canton of Zurich.
we detected a joinpoint in 2001 marking a change in the
incidence trend from ‘significantly increasing’ (APC
1981–2001: 1.5 (95% CI 1.1 to 1.9)) to ‘stable’ (APC
2001–2017: 0.3 (95% CI –0.2 to 0.8)). For colon/rectum
cancer, the AAPC over the whole study period was 0.1
(95% CI –0.2 to 0.3).
Mortality trends in general
Figures 1C and 1D present the sex-stratified mortality
trends for the respective cancer localisations from 1981 to
2017 in the canton of Zurich, Switzerland. The AAPCs are
displayed in table S1. In men, cancer mortality decreased
significantly and linearly for colon/rectum and lung cancer,
with AAPC of −2.4 (95% CI −2.6 to −2.1) and −2.5 (95%
CI −2.7 to −2.3), respectively. A joinpoint was detected for
prostate cancer in 1989 with a non-significantly increasing
trend from 1981 to 1989 (APC: 1.6 (95% CI −0.7 to 4.0))
and a significantly decreasing trend from 1989 to 2017
(APC: −2.8 (95% CI −3.1 to −2.5)). A non-significantly
decreasing trend was observed for melanoma throughout
the study period (AAPC: −2.4 (95% CI −5.4 to 0.8)).
In women, cancer mortality decreased linearly between
1981 and 2017 for colon/rectum cancer and for melanoma,
with statistically significant AAPC of −2.2 (95% CI −2.5
to −1.8) and −1.1 (95% CI −1.8 to −0.4), respectively. A
joinpoint was detected for breast cancer in 1987, mark-
ing the change from a non-significantly increasing trend
from 1981 to 1987 (APC: 1.8 (95% CI −1.3 to 4.9)) to
a significantly decreasing trend from 1987 to 2017 (APC:
-2.4 (95% CI −2.7 to −2.1)). For lung cancer, mortality
increased significantly throughout the study period with
AAPC of 1.9 (95% CI 1.5 to 2.3).
Incidence trends by age group and sex
Figure 2 shows the sex-stratified incidence trends by age
group. The AAPCs are displayed in table S2.
Men
In 1981, the age-standardised incidence of prostate cancer
was highest in the 70-79 age group, while in 2017 it was
highest in the 60-69 age group (fig. 2A). Prostate cancer
incidence was overall significantly increasing for the
younger age groups. In all age groups, we observed at least
one joinpoint distinguishing between an increasing trend in
earlier years and a decreasing trend in more recent years.
However, in the older age groups, the joinpoint was ob-
Table 1: Number of cancer cases by tumour localisation, sex and age group, 1981–2017, canton of Zurich, Switzerland.
Localisation ICD10 Men Women
Total <50 50-59/<60 60-69 70-79 ≥80 Total <50 50-59/<60 60-69 70-79 ≥80
Incidence
Breast C50 31,349 6744 6,598 7348 6259 4400
Prostate C61 31,673 3403 10,333 11,243 6694
Colon/rectum C18-C21 13,080 2758 3451 4115 2756 11,963 2,391 2544 3563 3465
Lung C33-34 15,361 3414 4840 4820 2287 7020 1,787 2005 2019 1209
Melanoma C43 6187 1403 1026 1418 1470 870 6247 2156 1,079 1102 1048 862
Mortality
Breast C50 9671 879 1467 1998 2374 2953
Prostate C61 8356 177 905 2679 4595
Colon/rectum C18-C21 5656 701 1112 1876 1967 5404 569 771 1523 2541
Lung C33-34 12,048 2119 3455 4081 2393 4911 971 1311 1527 1102
Melanoma C43 970 116 142 222 255 235 738 118 92 134 173 221
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served earlier (around 1990), while for the younger age
groups, the joinpoint was detected later (in 2002 and 2011,
respectively), indicating that the decreasing incidence
trend started earlier in older age groups. In the two middle
age groups, the incidence trend started to increase again in
2014.
For colon/rectum cancer in men, a decreasing trend was
observed in the two oldest age groups throughout the study
period (fig. 2C). In the youngest age group, we observed a
non-significantly increasing trend. The incidence rate was
highest in the 70–79 age group in both 1981 and 2017.
No joinpoints were detected, indicating linear trends. For
lung cancer in men, the incidence trends were similar in
all age groups, with highest incidence rates over the whole
period for the 60–69 age group (fig. 2E). The incidence
rates significantly decreased in all age groups over the
study period except for those aged ≥80 years. An increas-
ing trend for melanoma in men was observed in all age
groups with AAPC ranging between 1.2 and 5.2; larger
(positive) AAPC were observed for older age groups (fig.
2G). While in 1981 the incidence rate was highest in those
under the age of 50, the highest rates in 2017 were ob-
served for men aged 70–79 years.
Women
Breast cancer incidence in women was highest in the three
age groups up to 69 years both in 1981 and in 2017 (fig.
2B). The incidence trend was increasing in all age groups,
although it was only significant in women in the <50 and
Figure 2: Age-standardised incidence rates by age group for can-
cers of the prostate, breast, colon/rectum, and lung, as well as for
melanoma from 1981 to 2017, by sex, in the canton of Zurich.
70–79 age groups. Joinpoints in the age groups between 50
and 69 years indicated the steepest increase in the 1990s.
The incidence rate of colon/rectum cancer in women was
highest for the 70–79 age group in 1981, but highest for the
age group <60 years in 2017 (fig. 2D). An increasing trend
was observed in the youngest age group, a stable trend in
60–69-year-old women, and decreasing trends in the older
age groups. Lung cancer incidence increased significantly
in women in all age groups with AAPC ranging between
1.8 and 4.0; it was highest in those younger than 60 years
in 1981 and in those aged 60 to 69 years in 2017 (fig.
2F). An increasing trend for melanoma in women was ob-
served in all age groups (although not significant for those
aged 60-69 years) with AAPC ranging between 1.6 and
6.2; larger (positive) AAPC were observed for older age
groups (fig. 2H). The incidence rate was highest in the age
group <50 years throughout the study period.
Incidence trends by stage and sex
Figure 3 shows the sex-stratified incidence trends by stage
for the different localisations between 2003 and 2017. The
AAPC are displayed in table S3. The incidence trend for
‘missing stage’ information decreased for all localisations
and both sexes.
Figure 3: Age-standardised incidence rates by stage for cancers
of the prostate, breast, colon/rectum, and lung, as well as for
melanoma from 2003 to 2017, by sex, in the canton of Zurich.
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Men
For prostate cancer, the incidence was highest for stage II
tumours up to about 2010, and for stage I tumours there-
after (fig. 3A). Overall, the trends increased for stage I, III
and IV tumours and remained stable for stage II tumours
of the prostate. Several joinpoints indicated changes in the
trends by stage. Colon/rectum cancer in men significantly
increased for stage I and IV tumours, and significantly de-
creased for stage II tumours; the trend for stage III tumours
remained stable (fig. 3C). For lung cancer in men, an in-
creasing trend was observed for stage I, II and IV tumours,
although only significant for stage IV tumours (fig. 3E). A
stable trend was observed for stage III tumours. The inci-
dence rate was highest for stage IV tumours over the whole
study period. No joinpoints were detected for any of the
stages of lung cancer. The incidence of melanoma in men
increased for all stages, although it was only significant for
stage IV tumours (fig. 3G). The incidence rate was highest
for stage I tumours over the whole study period.
Women
In women, breast cancer incidence increased significantly
for stage I and stage IV tumours between 2003 and 2017,
while it decreased significantly for stage III tumours, and
remained stable for stage II tumours (fig. 3B). Over the
whole study period, the incidence of stage I and II tumours
was highest. The incidence of colon/rectum cancer in
women increased significantly for stage I and IV tumours,
decreased significantly for stage III tumours, and remained
stable for stage II tumours (fig. 3D). Overall, the incidence
rate was highest for stage III tumours in 2003 and 2017,
but similarly high for stage IV tumours in 2017. For lung
cancer in women, statistically significantly increasing
trends were observed for all stages, except for stage III tu-
mours (fig. 3F). Like in men, the highest incidence was ob-
served for stage IV tumours over the whole study period.
For melanoma in women, an increasing trend with AAPC
between 4.6 and 12.9 was observed for all stages, but it
was only significant for stage II tumours (fig. 3H). Like
in men, the incidence rate was highest for stage I tumours
over the whole study period. For both men and women, the
incidence trend in stage I tumours showed an interesting
shape: a non-significant decrease between 2003 and 2008,
extreme increases (AAPC >100) between 2008 and 2011,
and a levelling-off afterwards.
Mortality trends by age group and sex
Figure 4 shows the sex-stratified mortality trends by age
group and cancer localisation between 1981 and 2017. The
AAPC are displayed in table S2.
Men
Mortality associated with prostate, colon/rectum, and lung
cancer decreased significantly for men in all age groups,
except for lung cancer in men aged ≥80 years. For prostate
cancer, the highest mortality rates were observed in the
oldest age group (≥80 years), and the lowest rates in the
youngest age group (<60 years) over the whole study peri-
od (fig. 4A). For prostate cancer, we observed joinpoints in
1988 for the two middle age groups (60–79 years), indicat-
ing non-significant increases in mortality before 1988 and
significant decreases afterwards. For colon/rectum cancer
mortality, the highest mortality rates were observed in the
age groups above 70 years of age over the whole study pe-
riod (fig. 4C). Here, joinpoints were only observed in the
oldest age group (≥80 years), with a non-significantly in-
creasing trend from 1981 to 1990, a significantly decreas-
ing trend from 1990 to 2000, and a stable trend afterwards.
Regarding lung cancer, the highest mortality rates were ob-
served in the age groups 60 to 79 years throughout the
study period, and joinpoints were detected in the youngest
and oldest age group (fig. 4E). For melanoma mortality, the
rates were significantly decreasing for men under the age
of 60 years, while no significant trends were observed in
older men (fig. 4G). The mortality rate was highest in those
aged 60–69 years in 1981, and in those aged ≥80 years in
2017.
Women
Except in the most recent years, breast cancer mortality
was highest for women aged 60–69 (fig. 4B). In all age
groups, the mortality rates decreased; however, the pat-
terns were different. For example, in the age group 50-59, a
joinpoint indicated a steeper and significant decrease after
1993, while in women aged 60–69 years, the decrease was
steeper after 2005. For women aged ≥80 years, breast can-
cer mortality only decreased significantly between 1991
and 1999, with no significant trends before and after.
Colon/rectum cancer mortality in women decreased signif-
icantly in all age groups (fig. 4D). Over the observation
period, the mortality rates of colon/rectum cancer were
higher in older age groups, with lowest rates observed for
Figure 4: Age-standardised mortality rates by age group for can-
cers of the prostate, breast, colon/rectum, and lung, as well as for
melanoma from 1981 to 2017, by sex, in the canton of Zurich.
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women under the age of 60. Only one joinpoint was ob-
served for colon/rectum cancer in the oldest age group, in-
dicating a decreasing trend only up to 2009. Lung cancer
mortality in women was highest in women aged 60–69
years over the whole period (fig. 4F). It increased signifi-
cantly in all age groups, except the youngest where it re-
mained stable. In this age group, a joinpoint indicated a
significantly increasing trend between 1981 and 2008, and
a significantly decreasing trend thereafter. While the over-
all mortality rate for melanoma decreased in women be-
tween 1981 and 2017, the age-stratified decrease was on-
ly significant in the two youngest age groups (fig. 4H). In
women aged ≥80 years, the melanoma mortality rate in-
creased, although not significantly, throughout the study
period.
Discussion
Over the whole study period (1981–2017), the age-stan-
dardised incidence rates increased for prostate cancer,
breast cancer, and melanoma in both sexes, while lung can-
cer incidence rates increased only in women. A decreas-
ing rate was observed for lung cancer in men – potential-
ly reflecting the decreasing smoking prevalence in men
in Switzerland [10] – as well as for colon/rectum cancer.
The diverging trends in lung cancer incidence for men and
women are at least partly explained by the later onset of
smoking in women compared to men [11]. Regarding can-
cer mortality, the rates were significantly decreasing for all
localisations and both sexes, except for melanoma in men
(stable trend) and lung cancer in women (increasing trend).
Looking at age- and stage-stratified incidence trends for
prostate cancer, we observed joinpoints at different times
depending on the age group. While for men older than 70
years of age, the turning point from an increasing to a de-
creasing rate was around 1990, it was later for younger
men (after 2000). A steep increase in stage I tumours up
to 2011 may be associated with increased PSA screen-
ing behaviour in the early 2000s [12]. Furthermore, the
coding based on TNM classification of malignant tumours
changed in 2010 from version 6 [6] to version 7 [7], with
the result that T2a tumours were newly classified as stage
I instead of stage II tumours, which may explain the de-
crease in stage II tumours and the simultaneous increase in
stage I tumours.
Regarding breast cancer incidence, there was a steep in-
crease for women aged 50-69 years in the 1990s. Even
though there is no organised breast cancer screening pro-
gram in the canton of Zurich, increasing incidence in these
age groups may be an effect of the guidelines for mam-
mography screening for women aged ≥50 years [13, 14].
This is also in line with the increase in stage I tumours be-
tween 2003 and 2017.
Colon/rectum cancer incidence decreased in men in gen-
eral; however, when age-stratified, this decreasing trend
was only significant in men aged ≥70 years over the whole
study period. In women, the colon/rectum incidence trend
was stable overall; however, it was increasing in women
aged <60 years but decreasing in women aged ≥70 years.
An increasing trend in younger adults has been reported
in other high-income countries [15]. Possible explanations
are the changing prevalence and distribution of risk factors
for colorectal cancer in recent generations, such as excess
body weight, consumption of red and processed meat, al-
cohol consumption, smoking, and decrease in physical ac-
tivity, among others [15]. The decreasing incidence of
colon cancer in older individuals could be due to interven-
tions leading to the removal of adenomatous polyps [15].
In both men and women, incidence of stage I and IV tu-
mours of the colon/rectum was significantly increasing.
The increase of stage I tumors may be associated with an
increased use of colonoscopy in Switzerland in individuals
aged 55 years and older [16].
The increase in melanoma incidence observed in Zurich,
as in many other European countries [17], is probably the
result of an increased exposure to ultraviolet (UV) radi-
ation, especially during childhood, which, due to the lag
time, causes rising incidence rates in older adults [17]. The
smaller increase observed in younger adults may be a re-
sult of the increasing awareness of the risk factors for skin
cancer in the younger age group [17].
Comparison with other studies
For prostate cancer, an overall increasing incidence and de-
creasing mortality rate was reported for several European
countries [18, 19], including Nordic countries [20]. We ob-
served an increase in incidence up to 2002, and a decrease
thereafter (with some indication of a new increasing trend
after 2014), while for mortality we observed a significant
decrease since 1989. An increase in incidence is supported
by data from the French-speaking part of Switzerland for
the period from 1974 until at least 1994 (canton of Vaud)
[21], and from 1973 until about 2000 (canton of Geneva)
[22]. Increasing incidence was also observed in the Italian-
speaking part of Switzerland from 1996 until 2007 [12],
even though the rates in these regions were considerably
lower. The latter study was a comparison of prostate cancer
incidence between Zurich and Ticino for the period 1996 to
2013 [12]. A strong increase in incidence from the 1970s
or 1980s, up to around 2000-2005 and levelling off after-
wards, was reported in other European countries [23, 24].
Increasing trends in prostate cancer are likely associated
with the introduction of measuring blood-circulating lev-
els of prostate-specific antigen (PSA) as a screening instru-
ment in the 1990s. Even though some national and inter-
national organisations such as the US Preventive Services
Task Force and the Swiss Medical Board advise against
PSA testing for prostate cancer, this screening method is
quite frequent in Switzerland and increased between 1992
and 2012 [25].
Regarding breast cancer, both incidence and mortality
trends observed in Zurich are similar to trends reported
from northern European countries [19, 20]. Decreasing
trends in breast cancer mortality from around 1990 have
been reported in the EU in general, and specifically in Ger-
many, Italy, France, Spain, the UK [26], and in northern
European countries [19]. A study comparing breast can-
cer mortality in the French-speaking part of Switzerland
(with organised breast-screening since 1993 in the canton
of Vaud) with two German-speaking cantons without or-
ganised breast screening, reported a decrease of about 30%
between 1990 and 2000 in the French-speaking part com-
pared to no decrease in the German-speaking part [27].
Similar to our study, breast cancer incidence in younger
women increased in other European countries such as
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Spain, France, Italy, and Portugal [28], but also in Switzer-
land [29] and in Europe overall [30], potentially reflecting
an increase in mammography use. Data from the Swiss
Health Survey indicate that 44% of women aged 40 to 49
years already had a mammogram [31].
The relatively stable incidence rates for colon cancer in
Zurich are comparable to the results from several cantons
in Switzerland [16], as well as in other European countries
(e.g., Ireland and Denmark), but also Canada [32]. De-
creasing mortality rates are also widely observed in other
northern and western European countries [19, 32, 33], and
in the USA [34]. An increase in stage I and stage IV tu-
mours was also reported for other regions in Switzerland
[16].
A very similar picture to our study – with decreasing trends
in both incidence and mortality – was reported for lung
cancer in men all over the world, including Europe [19, 35,
36]. In women, an increase in incidence was observed in
several countries, especially in western, southern and east-
ern Europe, and some northern European countries, and al-
so in earlier publications of Zurich [10] and several other
Swiss cantons [37] looking at histological subtypes. Simi-
lar to our study, an increasing mortality rate was observed
in western, southern, eastern, and some northern European
countries [35, 36]. Because of different smoking behav-
iour in women compared to men (later onset of smoking
epidemic in women, lower smoking prevalence, and low-
er numbers of cigarettes smoked per day), lung cancer in
women occurred later [10, 38].
Similar to our results, the incidence of melanoma increased
in most other European countries for both sexes [17, 19,
39, 40], with mostly higher AAPC in the older age groups
[17]. Increasing trends have also been reported for the
French-speaking part of Switzerland between 1978 and
2002 [41], and in an earlier publication using data from the
canton of Zurich that looked at histological subtypes [42].
While mortality rates increased up to 2000 in several Euro-
pean countries [39], we did not observe such an increase.
While for prostate cancer, breast cancer, and melanoma,
the age-standardised incidence rates over the whole period
were highest for stage I and/or II tumours, the highest in-
cidence rates for colon/rectum and lung cancer were ob-
served for stage III (colon/rectum) and stage IV (lung)
tumours, respectively. This is in line with other studies
[43-47], and may be due to a lack of symptoms in early-
stage cancer for colon/rectum and (especially) lung cancer,
but also due to a higher prevalence of mammography and
PSA screening compared to lung and colorectal screening.
For all localisations, except for melanoma in women, the
age-standardised incidence rates increased for stage IV tu-
mours, indicating an increased frequency of higher-staged
tumours detected over time. However, this may also be as-
sociated with the simultaneous decrease in tumours with
‘missing stage’ information, especially if the missing in-
formation was not random (i.e., missing stage information
more likely in higher-staged tumours at earlier times).
Strengths and limitations
The strengths of this study include the long observation pe-
riod, the completeness of the data in the cancer registry [4],
and the stratification by age and stage. However, this study
had some limitations. The relatively large amount of miss-
ing information regarding stage, especially in earlier years,
only allowed the stratification by stage from 2003 onward.
Moreover, the increase observed in stages I to IV for sever-
al tumours is potentially driven by the decrease in missing
stage information over time, which was significant for all
tumours of interest in this study. In addition, the choice of
the joinpoint input parameters (such as the maximum num-
ber of joinpoints) influence, to some extent, the model out-
put. Furthermore, due to the heterogeneity regarding can-
cer registration in Switzerland, we only included data from
the canton of Zurich. Finally, parameters that may have in-
fluenced the observed trends (such as changes in screening
opportunities or new therapies) are not available on the in-
dividual level, and thus not included in the joinpoint mod-
els, which needs to be taken into consideration when inter-
preting the results.
Conclusions
This study presents the incidence and mortality trends for
the most common types of cancer from 1981 to 2017 in the
canton of Zurich, Switzerland. The overall increasing inci-
dence trends for prostate and breast cancer, as well as for
melanoma, are in line with data from other Western coun-
tries. While lung cancer incidence was decreasing in men,
it is still on the rise in women. Despite increasing inci-
dence rates, the mortality rates were decreasing for all lo-
calisations except for lung cancer in women, which reflects
the changing smoking patterns and increasing lung cancer
incidence in women. The opposite direction of the inci-
dence and mortality curves could be attributed to increased
awareness, screening, and better/more effective treatment
options. Decreasing mortality rates are good news for can-
cer patients. With more advanced treatments, this decline
will hopefully continue. The increasing trends in lung can-
cer incidence and mortality in women are alarming and
highlight the need for public health measures, in order
to reduce smoking prevalence and prevent young women
from starting smoking.
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Appendix 1
Supplementary tables
Table S1: Average Annual Percentage Changes (AAPC)
for incidence and mortality trends by tumour localisation
and sex, 1981–2017, canton of Zurich, Switzerland.
Table S2: Average Annual Percentage Changes (AAPC)
for incidence and mortality trends by tumour localisation,
age group, and sex, 1981–2017, canton of Zurich, Switzer-
land.
Table S3: Average Annual Percentage Changes (AAPC)
for incidence trends by tumour localisation, stage, and sex,
2003-2017, canton of Zurich, Switzerland.
The appendix is available as a separate file at
https://smw.ch/article/doi/smw.2020.20388.
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